The Time Is Now for New Biosafety Testing Services

Armstrong SE , Mariano JA , Lundin DJ . The scope of mycoplasma contamination within the biopharmaceutical industry. Biologicals , 2010; 38: 211–213.

U.S. Government. Code of Federal Regulations. Title 21, Subpart D-Mycoplasma §610.30. Amended April 1998. Removed September 2020.

U.S. Government. Code of Federal Regulations. Title 21, §610.18(c): Cell lines used for manufacturing biological products. 2010.

United States Pharmacopeia. <63> Mycoplasma Tests. 2010.

European Pharmacopoeia. Chapter 2.6.7 Mycoplasmas. 2008.

U.S. Food and Drug Administration. Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications. Guidance for Industry. February 2010.

U.S. Food and Drug Administration. Long Term Follow-Up after Administration of Human Gene Therapy Products. Guidance for Industry. January 2020.

U.S. Food and Drug Administration. Human Gene Therapy for Neurodegenerative Diseases. Guidance for Industry. October 2022.

U.S. Government. Code of Federal Regulations. Title 21, Subpart B-General Provisions, §610.9: Equivalent Methods and Processes. 2010.

U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Human Somatic Cell Therapy and Gene Therapy. Guidance for Industry. March 1998.